Positive Voice Of Kenya

  As Kenya’s population grows and the burden of disease evolves, access to affordable and high-quality medicines has become a national priority. Historically, the country has relied heavily on pharmaceutical imports, with more than 70% of drugs sourced from foreign manufacturers. However, the tide is beginning to turn. Driven by the need for supply chain security, lower medicine costs, and greater healthcare independence, Kenya is witnessing the rise of local pharmaceutical manufacturing . Among the industry’s notable contributors is Jayesh Saini , founder of Dinlas Pharma , who has invested significantly in boosting domestic production capabilities. This article explores the state of Kenya’s pharmaceutical industry , the challenges and opportunities in local manufacturing , and whether the country is truly ready to meet its growing demand. 1. The Case for Local Pharmaceutical Manufacturing 1.1 Why Local Production Matters Import dependency exposes Kenya to global supply disruptio...

Africa’s reliance on imported medicines—up to 70% in many countries—has long exposed the continent to supply chain disruptions, price volatility, and limited access to essential drugs . The COVID-19 pandemic made these vulnerabilities even more apparent, as global shortages and export restrictions threatened the availability of life-saving treatments across Africa. In response, a movement toward pharmaceutical self-reliance has gained momentum, with countries like Kenya emerging as regional leaders in local drug manufacturing . One of the key drivers of this transformation is Jayesh Saini , founder of Dinlas Pharma , whose large-scale production capacity and distribution network are helping Kenya reduce its dependency on imports and build a more resilient and accessible healthcare system . This article explores the importance of local pharmaceutical production in reshaping Africa’s medical supply chain, focusing on Kenya’s progress and the role of Dinlas Pharma in delivering high-qual...